Fulcrum Therapeutics, Inc.
FULCNasdaqCIK 1680581HealthcareFiscal year ends Dec 31
Reports and events: 127 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-1708:30 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.01 Change in control; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-353278 |
| 2026-08-1008:43 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-341385 |
| 2026-07-3016:05 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-326098 |
| 2026-06-2516:32 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-282873 |
| 2026-06-1116:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-267659 |
| 2026-06-0416:05 ET | 8-K | 2.05 Exit or disposal costs; 8.01 Other events | 0001193125-26-257376 |
| 2026-06-0116:05 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-251394 |
| 2026-04-3016:06 ET | DEF 14A | Proxy statementPeriod 2026-06-24 | 0001193125-26-197196 |
| 2026-04-2707:10 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-178814 |
| 2026-04-2707:05 ET | 8-K | 1.02 Termination of a material agreement; 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-178806 |
| 2026-02-2407:10 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-065197 |
| 2026-02-2407:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-065190 |
| 2026-01-1208:18 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-009845 |
| 2025-12-1121:36 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-314728 |
| 2025-12-0806:32 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-310509 |
| 2025-10-2907:10 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-254633 |
| 2025-10-2907:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-254619 |
| 2025-08-2810:41 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-190746 |
| 2025-07-2908:39 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-099407 |
| 2025-07-2908:34 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-099404 |
| 2025-06-2716:14 ET | 8-K | 5.07 Shareholder vote results | 0001193125-25-151276 |
| 2025-05-0107:10 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-061442 |
| 2025-05-0107:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-061439 |
| 2025-04-3016:00 ET | DEF 14A | Proxy statementPeriod 2025-04-25 | 0000950170-25-061000 |
| 2025-03-0417:00 ET | 8-K | 1.02 Termination of a material agreement | 0000950170-25-032355 |
| 2025-02-2507:10 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-026068 |
| 2025-02-2507:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-026063 |
| 2025-01-1307:00 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-004942 |
| 2024-12-2316:30 ET | 8-K | 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001193125-24-284214 |
| 2024-11-1307:10 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-125931 |
| 2024-11-1307:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-125927 |
| 2024-11-1217:21 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-24-256101 |
| 2024-09-2416:05 ET | 8-K | 2.05 Exit or disposal costs; 9.01 Financial statements and exhibits | 0000950170-24-109069 |
| 2024-09-1212:43 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-217822 |
| 2024-08-2216:02 ET | 8-K | 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-24-205347 |
| 2024-07-3107:15 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-088238 |
| 2024-07-3107:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-088236 |
| 2024-06-1716:37 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001193125-24-162653 |
| 2024-05-1307:15 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-058193 |
| 2024-05-1307:05 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-058187 |
| 2024-04-1916:05 ET | DEF 14A | Proxy statementPeriod 2024-06-17 | 0001193125-24-102863 |
| 2024-02-2716:01 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-021074 |
| 2024-02-2707:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-020615 |
| 2023-11-0707:05 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-059755 |
| 2023-11-0707:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-059753 |
| 2023-10-0216:01 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-23-249011 |
| 2023-08-2207:01 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-23-217439 |
| 2023-08-0307:11 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-037579 |
| 2023-08-0307:05 ET | 8-K | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-23-037574 |
| 2023-07-1017:06 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-23-184748 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 27, 2026, 16:11 ET. Listed shows no prices and gives no investment advice.